Overview

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Status:
RECRUITING

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the effect of steady-state NAL ER on the pharmacokinetics (PK) of pirfenidone or nintedanib and the effect of steady-state pirfenidone or nintedanib on the PK of NAL ER in healthy participants.

Phase:

PHASE1

Details

Lead Sponsor:

Trevi Therapeutics

Treatments:

nintedanib
pirfenidone